ICE_PACK
Financiado
Polymer Materials for Cryogenic Storage and Distribution of Biologics
Ten years ago small molecules were the drugs of choice for most diseases. This situation has dramatically changed such that in 2017, 4 in 5 of the best-selling drugs were proteins, delivering major healthcare benefits from cancer...
Ten years ago small molecules were the drugs of choice for most diseases. This situation has dramatically changed such that in 2017, 4 in 5 of the best-selling drugs were proteins, delivering major healthcare benefits from cancer to infectious disease. Cell-based therapies are also emerging, with the promise of making the incurable, curable (especially in oncology). However, the use of these ‘biologics’ has accelerated beyond the currently available technologies to stabilize these therapeutics against the environmental stresses imposed by the pharmaceutical cold chain. 75 % of current biologics must be cryopreserved to ensure they reach the patient in a functional format, requiring the addition of cryoprotectants (organic solvents) which are toxic, do not enable full post-thaw recovery, are complex to remove, do not stabilize cell membranes efficiently, lead to batch-to-batch post-thaw variabilities in function and cause toxic plasticizers to leach from transport bags.
ICE_PACK will develop unprecedented macro-and supra-molecular biomaterials to transform the biologic cold chain with long term impact by making these therapies more effective, cheaper, safer and more widely available.
We will synthesize polymeric cryoprotectants, inspired by Nature’s macromolecular ice modulators, capable of inducing ice nucleation, stabilising cell membranes and protecting proteins from denaturation, and apply these to cryopreserve real therapeutics. An integrated approach will be taken whereby ice nucleation and growth control will be studied in parallel to investigating the biochemical and molecular biology impact of cold stresses. Major fundamental scientific advances will also emerge, linking macromolecular structure to ice nucleation and to biochemical pathways of cold tolerance and stress.
The long term outcomes of this ground breaking ERC project will be the transformation of cryopreservation strategies, suitable for 21st Century biologic medicines.
ver más
Duración del proyecto: 90 meses
Fecha Inicio: 2020-02-03
Fecha Fin: 2027-08-31
Fecha Fin: 2027-08-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2020-02-03
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2019-COG:
ERC Consolidator Grant
Cerrada
hace 5 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
THE UNIVERSITY OF MANCHESTER
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
197.20K€ |
Participante